Lung Squamous Cell Carcinoma Clinical Trial
Official title:
Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting GPC3 for the Treatment of Recurrent or Refractory Lung Squamous Cell Carcinoma
The purpose of this study is to observe and confirm the safety, tolerance and cell pharmacokinetics of lentivirus-transduced CAR-GPC3 T cells (CAR-GPC3 T cells targeting GPC3)
A single-center, open-label pilot study to determine the safety, tolerance and engraftment
potential of CAR-GPC3 T cells in subjects with GPC3+ positive lung squamous cell carcinoma.
Primary objectives:
Observe and determine the safety and tolerance in escalating dose infusion of CAR-GPC3 T
cells (CAR T cells targeting GPC3) transduced with the lentiviral vector, and the survival
of the CAT-GPC3 T cells in vivo, referred to as engraftment potential.
Secondary objectives:
The following indexes are monitored for curative effect of CAR-GPC3 T cells on lung squamous
cell carcinoma:
1. Objective response rate (ORR), is defined as the ratio of patients diagnosed as partial
remission (PR) to complete remission (CR) according to RECIST 1.1 criteria.
2. Progression free survival (PFS), is defined as the duration from baseline to PD
(audited and confirmed by independent imaging), or to the day of any death event. The
earlier one shall prevail.
3. Time to tumor progression (TTP), is defined as the duration from baseline to disease
starts to get worse or spreads to other parts of the body.
4. Overall survival (OS), is defined as the time period from the 1st day of treatment to
the day of death for any reason. For patients who are still alive at the data analysis
day, OS data is subject to the last confirmed time of survival patients.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04267913 -
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
|
Phase 2 | |
| Not yet recruiting |
NCT03725423 -
Apatinib for Advanced Lung Squmamous Carcinoma
|
Phase 4 | |
| Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
| Recruiting |
NCT04132102 -
To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
|
Phase 4 | |
| Active, not recruiting |
NCT04152018 -
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
|
Phase 1 | |
| Recruiting |
NCT05778253 -
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
|
||
| Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT01386385 -
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00334815 -
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Recruiting |
NCT05782764 -
A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
|
Phase 4 | |
| Recruiting |
NCT05010330 -
Identify Prognostic Biomarkers of Lung Cancer
|
||
| Recruiting |
NCT06436040 -
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
|
||
| Recruiting |
NCT05024266 -
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04802876 -
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
|
Phase 2 |